Search bioRxiv⌕ Search

Biology subjects

Zok, S.

Publications and source records attributed to Zok, S..

3 recordsLinked to original sources

MAGI: Mechanistic Consequences of Genetic Variants via Genomic Foundation Models

Clinical variant interpretation requires mechanism-aware evidence to guide diagnosis and clarify the biological consequences of mutations. However, existing computational predictors and genomic foundation models largely function as black boxes, providing pathogenicity labels with limited mechanistic insight or clinical actionability. Here, we present MAGI (Mechanistic Annotation of Genomic Impacts), a novel method that bridges this interpretability gap by unifying clinically relevant variant interpretation with mechanistic genomic analysis. MAGI pipeline leverages a genomic transformer model to quantify the effects of DNA variants across 3,623 functional tracks, encompassing regulatory features, multi-omics datasets, including tissue specificity and chromatin states, and 21 additional molecular annotations of genes and transcripts. These signals are integrated through a deterministic logic layer that maps single-nucleotide variants and indels to explicit molecular consequences. We benchmark MAGI-derived consequences against clinical rationales curated from ClinVar and observe strong concordance that scales with the magnitude of functional disruption. MAGI accurately recapitulates canonical pathogenic mechanisms, including start codon loss, splice site disruption, and regulatory element perturbation, consistent with ClinVar annotations. We further present case studies addressing conflicting or incomplete mechanistic interpretations, as well as variants requiring complex inference. Notably, MAGI is also applicable to non-human genomes and was evaluated on multispecies OMIA pathogenic variants. Collectively, MAGI establishes a generalizable framework that extends beyond clinical diagnostics to enable mechanistic discovery in functional genomics, generating mechanistically grounded, testable hypotheses for variants of uncertain significance (VUS) and variants with discordant clinical interpretations. In several cases, MAGI proposes alternative explanations that challenge existing annotations, providing transparent rationales and experimentally tractable predictions.

genetics↗

Signatures of Micropeptides Encoded by lncRNAs in Cancer Progression and Metastasis

Long non-coding RNAs (lncRNAs) are key regulators of gene expression, chromatin remodeling, and signaling. Recent estimates suggest that the human genome contains more than 35,000 lncRNA genes, with roughly 20% predicted to encode micropeptides (MPs) with unknown functions. In this study, we focused on the subset of lncRNAs with strong statistical evidence for MP-encoding potential, accounting for approximately 8% of the unfiltered MPs collection. Our analysis centered on 1,782 high-confidence lncRNA-MPs derived from 478 genes expressed across 17 cancer types from The Cancer Genome Atlas (TCGA). We show that lncRNA-MPs display distinct amino acid compositions and unique 4-mer patterns compared to the human coding proteome. A few genes (9) with exceptionally long transcripts are characterized by [≥]20 MPs each. Functional interference confirmed that most of the lncRNA-MPs are unstructured. Only a third of the genes display some phylogenetic conservation, and only 4 genes display canonical N-terminal signal peptides characteristic of secreted proteins. We focused on cancer progression-associated lncRNAs that show differential expression (z-score >|3|) across consecutive tumor stages and metastatic states (transitional lncRNAs, Tr-lncRNAs). A collection of 72 genes encoding 314 MPs (Tr-lncRNA-MPs) was detected, with 76% of the MPs being [≥]30 amino acids long. Prediction by AlphaFold 2.0 and homology modeling tools revealed dozens of MPs with well-defined secondary structures and recognizable 3D motifs. Among the longer Tr-lncRNA-MPs (>60 amino acids), we confirmed the presence of ubiquitin-like, RNase H-related, and other conserved foldable motifs. Known cancer lncRNAs containing high-confidence MPs (XIST, UCA1, HOXA11-AS, LINC01234, and HAND-AS1) overlap with 50 pan-cancer lncRNAs associated with tumor stage or metastasis transitions. Together, these findings demonstrate that integrating sequence motifs (e.g., signal peptides, k-mers) with structural foldability offers a multifaceted view of lncRNA-MPs in cancer. We argue that the capacity to produce MPs may reinforce the oncogenic impact dominated by the lncRNA entity. We propose that Tr-lncRNA-MPs represent a promising new class of biomarkers and therapeutic targets in oncology. Key pointsO_LI478 lncRNA genes with strong evidence for micropeptide (MPs) production generated 1,782 distinct lncRNA-MPs. C_LIO_LI72 lncRNAs and 314 MPs are associated with transitional lncRNAs from 17 cancer types and stages of tumor progression and metastasis. C_LIO_LISequence and structural analyses reveal many MPs with reliable 3D folding potential. C_LIO_LIDozens of previously overlooked MPs may serve as novel biomarkers and therapeutic targets in cancer. C_LI

cancer biology↗

Transitional lncRNA Signatures Reveal Distinct Stages of Cancer Progression and Metastasis

Long non-coding RNAs (lncRNAs) are emerging as key regulators in cancer, influencing gene expression, chromatin remodeling, and signaling. Evidence from The Cancer Genome Atlas (TCGA) and other datasets supports their role in tumor progression. Although the human genome harbors thousands lncRNA genes, only a small subset has been validated in cancer. In this study, we used the LncBook catalog ([~]95,000 lncRNAs) to identify [~]12,500 lncRNAs with expression evidence across major TCGA cancer types. These were stratified by clinical annotations, including cancer stage (I-IV) and metastatic state (M0/M1). Using significant differential expression (z-score >|3|) for consecutive transitions, we identified a set of influential transitional lncRNAs (Tr-lncRNAs) that signify cancer transitions. Analyzing seven transitions revealed that over 70% of Tr-lncRNAs were cancer-type specific, while only 2-4% were shared across 17 major cancers. Each cancer type had 30-80 Tr-lncRNAs, with more than half uniquely expressed in one type. Most Tr-lncRNAs were previously uncharacterized. A pan-cancer analysis revealed 14 shared Tr-lncRNAs, including known ones such as XIST and H19. Our findings highlight distinct lncRNA expression patterns during cancer progression and provide new insights into cis-regulatory antisense mechanisms. We discuss the potential of Tr-lncRNAs as diagnostic biomarkers and therapeutic targets in cancer.

cancer biology↗